Importantly, interrogating the structural details of BZA-ERα LBD binding suggests that molecules with improved pharmacological profiles that specifically disrupt the H11-12 loop at H12 will have clear advantages against breast cancer cells expressing WT, Y537S, and D538G ERα. Here, ESR1 is linked to breast cancer.